MedTrace Logo

Regulatory Post Marketing Surveillance Study on Nexavar®

NCT01012011 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2845

Last updated 2015-09-21

No results posted yet for this study

Summary

This surveillance are to identify problems/questions regarding adverse events, factors that are considered to affect on safety and efficacy in the clinical practice of using Nexavar

Conditions

  • Carcinoma, Hepatocellular
  • Carcinoma, Renal Cell

Interventions

DRUG

Sorafenib (Nexavar, BAY43-9006)

Daily dose, dosage frequency and duration will be decided by physicians.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
20 Years
Max Age
91 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2015-01-31
Completion
2015-08-31

Countries

  • South Korea

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01012011 on ClinicalTrials.gov